Merck Finds Covid Pill is Less Effective Than Previously Estimated greekreporter.com
Merck said on Friday that its anti-Covid pill was found to be 20% less effective in a final analysis of a clinical trial.
Report Story“The evidence points to this being yet another derivative-induced selling event,” wrote J.C. Parets, chief market strategist for All Star…
The fabulous, ever-evolving transdisciplinary artist Colette Lumiere, who “died” at the Whitney in 1978 and was reborn as the executor…
BurgerMania weekend Fr-Sa !!!
must-hit holiday bars for all your merrymaking in NYC
A CDC spokeswoman confirmed the agency is working to modify its global testing rules for travel "as we learn more…
1 Comment
Despite the significant drop in efficacy, some experts are anticipating an emergency approval for the drug. Dr. David Boulware, who researches infectious disease at the University of Minnesota, told The New York Times that “The reduction in hospitalization is a little bit less, but there is still a big mortality benefit if you start early.”
Pfizer has been developing its own oral medication for Covid simultaneously to Merck, and found the treatment to be 89% effective at reducing hospitalization and death.
The pill, called Paxlovid, has also been submitted for emergency authorization by the FDA. Pfizer officially completed its application for emergency use authorization last week, but it has not yet been announced when the agency will make a decision regarding the drug.